Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- OPHT +11.4%, AMD +9.4%, X +7.6%, SFS +7.4%, EXAS +7.2%, RCKY+3.8%, TRN +3.6%, RES +3.6%, SLAB +3.5%, SN +3.5%, ZION +3%, BGCP+2.8%, T +2.7%, CMG +2.6%, WES +2.1%, STM +1.9%, BA +1.7%, LUV+1.7%, CMRE +1.6%, BAX +1.5%, APH +1.5%, TSS +1.4%, NYCB +1.4%,IVTY +1.3%, LEA +1%
M&A news:
- IRBT +20.6%, (to acquire privately-held Robopolis SAS for $141 mln )
- GUID +2.8% (o be acquired by OpenText (OTEX) for $7.10 per share)
- SNI +1.3% (Viacom (VIAB) said to be willing to make an all-cash offer for Scripps, according to Reuters)
- SHPG +1% (renewed M&A speculation)
Other news:
- TTPH +28.6% (Tetraphase Pharmaceuticals announces top-line results from IGNITE4, the Company's phase 3 clinical trial evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of patients with complicated intra-abdominal infections)
- ARGS +25% (announces publication of immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection in the Journal of AIDS Research and Human Retroviruses)
- ETRM +19.3% (enters into Collaboration Agreement with Galvani Bioelectronics Limited)
- MDGS +5.1% (distribution agreement in Switzerland and Liechtenstein with ADMEDICS)
- BLRX +2.2% (announces that BVF Partners will make an additional, direct investment of $9.6 million in BioLineRx, increasing its economic interest in the Company to 24.9%)
- EVGN +2.2% (enter into multiyear collaboration with DuPont)
- NVDA +1.4% (in sympathy with AMD)
Analyst comments:
- OCUL +3.7% (initiated with a Buy at H.C. Wainwright)
- EA +2% (upgraded to Buy from Neutral at BofA/Merrill)
- DSW +1.9% (upgraded to Outperform from Neutral at Wedbush)